1. Home
  2. NKTX vs ELDN Comparison

NKTX vs ELDN Comparison

Compare NKTX & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.09

Market Cap

132.8M

Sector

Health Care

ML Signal

HOLD

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$1.73

Market Cap

123.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTX
ELDN
Founded
2015
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.8M
123.1M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
NKTX
ELDN
Price
$2.09
$1.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$13.25
$8.50
AVG Volume (30 Days)
708.2K
863.5K
Earning Date
11-10-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$1.35
52 Week High
$2.74
$4.97

Technical Indicators

Market Signals
Indicator
NKTX
ELDN
Relative Strength Index (RSI) 69.68 51.29
Support Level $1.79 $1.44
Resistance Level $2.22 $1.76
Average True Range (ATR) 0.08 0.08
MACD 0.04 0.05
Stochastic Oscillator 75.73 90.48

Price Performance

Historical Comparison
NKTX
ELDN

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Share on Social Networks: